Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unicycive Therapeutics filings document the regulatory, financing, governance, and operating disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on kidney disease therapies. Form 8-K reports furnish financial results and business updates, including disclosures related to oxylanthanum carbonate, NDA activity, manufacturing matters, and the company’s cash and capital resources.
The filing record also covers common stock registered on the Nasdaq Capital Market, emerging growth company status, at-the-market equity sales under a shelf registration statement, and board and executive-governance matters. Proxy materials document director elections, auditor ratification, stockholder voting mechanics, and annual meeting procedures, while other current reports address securities litigation risk tied to public statements about the OLC program.
Unicycive Therapeutics, Inc. held its Annual Meeting of Stockholders on June 19, 2025, with 14,964,159 common shares represented, constituting a quorum. Stockholders elected three directors — Dr. Shalabh Gupta, Dr. Sandeep Laumas, and D. Sarawati Kenkare‑Mitra — to serve until the 2027 annual meeting or until successors are elected and qualified.
Support for the nominees ranged from 7,510,434 to 8,131,958 votes "for," with broker non‑votes exceeding 6.6 million for each. Stockholders also ratified the appointment of Grassi & Co. CPAs, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 14,667,242 votes in favor, 286,958 against, and 9,928 abstentions.
Gupta Shalabh K. reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics reported that CEO Shalabh K. Gupta received a grant of 762,200 restricted stock units (RSUs) payable in common stock. These RSUs are a form of equity compensation, not an open-market purchase or sale.
According to the award terms, 105,861 shares vest immediately upon grant. An additional 21,172 shares vest over 31 months beginning on June 1, 2026, contingent on Gupta’s continued service with the company. Following this grant, the Form 4/A shows Gupta holding 762,200 RSUs linked to common stock.
Kenkare-Mitra Sara reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sara Kenkare-Mitra received two new restricted stock unit (RSU) awards as equity compensation. On May 14, 2026, she was granted 42,100 RSUs and a separate 84,200 RSU annual award, each payable solely in common stock.
For the 42,100-unit RSU award, 11,694 shares vest immediately, with 2,339 shares vesting monthly over 31 months beginning June 1, 2026, subject to her continued service. For the 84,200-unit annual RSU award, 17,542 shares vest upon grant and 3,508 vest monthly over 7 months starting the same date.
Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics director Sandeep Laumas received two equity compensation grants in the form of restricted stock units (RSUs). The Form 4/A reports awards covering 42,100 and 84,200 RSUs, each payable solely in Unicycive common stock.
Footnotes explain that one RSU award provides 11,694 shares vesting upon grant and 2,339 shares vesting monthly over 31 months beginning June 1, 2026, subject to his continued service. A second annual RSU award provides 17,542 shares vesting upon grant and 3,508 shares vesting monthly over 7 months beginning the same date, also contingent on continued service. These are compensation-related grants at a stated price of $0.00 per unit, not open‑market share purchases or sales.
Gupta Pramod reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics, Inc. reported that EVP, Pharmaceuticals and BD, Pramod Gupta received a grant of 169,500 restricted stock units (RSUs) payable solely in common stock. This is a compensation-related award, not an open-market share purchase or sale.
According to the award terms, 23,542 shares vest upon grant, and 4,708 shares vest monthly over 31 months beginning on June 1, 2026, subject to Gupta’s continued service with the company. Following this grant, his reported derivative holdings from this RSU award total 169,500 underlying shares.
Townsend John reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics CFO John Townsend received a grant of 169,500 restricted stock units (RSUs) tied to the company’s common stock. This is a stock-based compensation award, not an open-market share purchase or sale.
According to the footnote, 23,542 shares vest upon grant, and an additional 4,708 shares vest over 31 months beginning on June 1, 2026, as long as he continues to serve at the company. Following this award, Townsend is shown as directly holding 169,500 RSUs, aligning his compensation more closely with the company’s future stock performance.
Jermasek Douglas reported acquisition or exercise transactions in this Form 4 filing.
Unicycive Therapeutics EVP Douglas Jermasek received a grant of 169,500 restricted stock units payable in common stock. According to the award terms, 23,542 shares vest immediately on grant and 4,708 shares vest monthly over 31 months beginning on June 1, 2026, contingent on continued service.
Unicycive Therapeutics, Inc. entered into a second amendment to its sales agreement with Guggenheim Securities to expand its at-the-market common stock offering capacity to $150,000,000. The at-the-market program allows the company to sell shares of common stock from time to time.
On the same date, Unicycive filed a Shelf Registration Statement on Form S-3, including a sales agreement prospectus, to register up to $50,000,000 of common stock for sale under this at-the-market offering. The amendment itself is incorporated by reference as an exhibit.
Unicycive Therapeutics, Inc. is registering up to $150,000,000 of securities on a shelf registration, including up to $50,000,000 of common stock that may be sold under a Sales Agreement with Guggenheim Securities, LLC.
Subsequent to March 31, 2026, pursuant to the Sales Agreement, the Company sold 1,693,000 shares of common stock at an average price of $7.34 per share for net proceeds of approximately $11.2 million. Shares of common stock issued and outstanding were 27,393,027 as of June 5, 2026. The prospectus describes multiple distribution methods and states that specific terms for any offering will be provided in a prospectus supplement.
Separately, the Company disclosed regulatory progress for its oxylanthanum carbonate NDA: the FDA accepted a resubmission as a Class II complete response with a PDUFA target action date of June 29, 2026.